Zastosowanie preparatu Avastin w leczeniu postaci wysiękowej degeneracji plamki związanej z wiekiem, makulopatii cukrzycowej i retinopatii cukrzycowej proliferacyjnej - wyniki badania pilotażowego
The Use of Avastin in the Treatment of Exudative Form of Age-related Macular Degeneration, Diabetic Macular Edema and Proliferative Diabetic Retinopathy - Early Result of the Pilot Study
Iwona Grabska-Liberek, Agnieszka Nowosielska, Katarzyna Gurdziel
Oddział Kliniczny Okulistyki Centrum Medycznego Kształcenia Podyplomowego Samodzielnego Publicznego Szpitala Klinicznego im. prof. W. Orłowskiego w Warszawie P.o. kierownik: dr n. med. Iwona Grabska-Liberek
Summary: Purpose: The aim of this paper is to describe the results of six week, open label, pilot study of intravitreal Avastin administration in cases of exudative form of age-related macular degeneration, diabetic macular edema and proliferative diabetic retinopathy. Material and methods: There were 6 patients enrolled into the trial, who all gave written consent. Avastin was given only to one eye of each patient. The given dosage was 1.25 mg/ 0.05ml. The drug administration took place in operating room under the local anesthesia. Results: All patients participating in the pilot study gain some vision in the treated eye and remained stable during 6 week follow-up period. However improvement in case of AMD patients was limited. The best result was achieved in diabetic patients. Conclusions: Avastin seems to be save and effective drug while used intravitreally. No major adverse event during or up to 6 weeks after administration were noted. The vision improvement in our opinion is mostly dependent on the state of the basic disease. Further studies are needed to assess the long-term safety and efficacy of this promising drug.
Keywords: retinal laser treatment, complications, side effects.